stockrow
Friday 6 November 2026
Export INSM’s income statement to Excel — free account
Insmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.
- Revenue
- +268.4%
- EPS
- +73.8%
- Free cash flow
- +81.1%
- Total debt
- +0.27%
Quarter to September 2026, against a year earlier
114.36
5.60
+5.15%
Follow INSM
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
57.12 | 42.99 | 20.37 | 16.43 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(139.89) | (158.18) | (260.89) | (684.93) | |
P/B ratio |
46.87 | 49.99 | 30.59 | 34.39 | |
Price to Tangible BV |
68.56 | 74.46 | 43.90 | 55.29 | |
EV/Sales |
56.05 | 42.46 | 20.04 | 16.20 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(36.35) | (38.85) | (29.27) | (41.32) | |
EV/FCF |
(35.13) | (37.75) | (28.23) | (39.22) | |
Quick Ratio |
3.35 | 3.88 | 3.14 | 2.36 | |
Current Ratio |
3.83 | 4.47 | 3.72 | 2.86 | |
Net Debt/EBITDA |
2.78 | 4.52 | (102.75) | 7.41 | |
Debt/Assets |
24.80% | 27.07% | 26.75% | 25.28% | |
Debt/Equity |
0.76 | 0.80 | 0.74 | 0.78 | |
Asset Turnover |
0.28 | 0.42 | 0.50 | 0.66 | |
Operating CF/Net income |
0.75 | 1.36 | 6.71 | 0.36 | |
Capex/Depreciation |
(2.18) | (0.49) | (0.85) | (0.53) | |
Interest Coverage |
(15.52) | (7.63) | (0.08) | (4.38) | |
Research and Development Expense of Revenue |
96.61% | 68.47% | 49.36% | 51.48% | |
Selling, General and Administrative Expense of Revenue |
80.53% | 80.81% | 58.16% | 48.25% | |
Intangible Assets out of Total Assets |
0.10 | 0.11 | 0.11 | 0.12 | |
Share Based Compensation of Revenue |
14.80% | 14.95% | 9.70% | 7.86% | |
Graham Net Nets |
0.01 | 0.01 | 0.01 | 0.01 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(3.68%) | (3.52%) | (3.85%) | (2.47%) | |
Free Cash Flow Yield |
(2.79%) | (2.62%) | (3.49%) | (2.51%) | |
Revenue per Share |
1.33 | 1.42 | 1.96 | 2.40 | |
Operating CF per Share |
(1.24) | (1.03) | (0.41) | (0.17) | |
Capex per Share |
(0.08) | (0.02) | (0.03) | (0.03) | |
Free Cash Flow per Share |
(1.33) | (1.05) | (0.44) | (0.19) | |
Cash per Share |
7.19 | 5.68 | 5.34 | 5.24 | |
Shareholders Equity per Share |
3.71 | 3.27 | 3.49 | 3.32 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.71 | 3.27 | 3.49 | 3.32 | |
Free Cash Flow |
(264.18) | (226.22) | (95.09) | (42.08) | |
Working Capital |
1,325.33 | 1,252.17 | 1,195.18 | 1,109.93 | |
Capital Expenditures |
(16.59) | (3.48) | (6.26) | (5.62) | |
Net Current Asset Value |
268.63 | 242.16 | 288.85 | 206.67 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.06 | 0.01 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
96.43 | 113.15 | 135.18 | 162.26 | |
Average Payables |
370.63 | 292.61 | 366.97 | 492.19 | |
Average Inventory |
115.32 | 116.81 | 124.99 | 142.46 | |
Average Assets |
2,144.89 | 1,939.30 | 2,291.21 | 2,293.40 | |
Average Common Equity |
512.18 | 402.01 | 1,003.61 | 835.89 |
Columns are period end dates · fundamentals updated 2 Nov 2026